Literature DB >> 16060867

A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.

Ercan Arca1, Osman Köse, A Hakan Erbil, Mustafa Nişanci, Ahmet Akar, Ali Riza Gür.   

Abstract

Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe skin reactions, usually to drugs, associated with a widespread destruction of the epidermis. Widespread purpuric macules and epidermal detachment of less than 10% of the body surface is indicative of Stevens-Johnson syndrome, whereas epidermal detachment between 10% and 30% is called Stevens-Johnson-toxic epidermal necrolysis overlap. Epidermal detachment involving more than 30% of the total body surface is designated as toxic epidermal necrolysis. These generalized reactions are known to occur in association with various drugs. Treatment is primarily supportive care, and there are no specific therapy regimens. Therapeutic modalities such as corticosteroids, cyclosporin, thalidomide, cyclophosphamide, and plasmapheresis, usually based on a symptomatic approach, have been tried in single patients or in small series. Intravenous immunoglobulin has recently been shown to provide rapid improvement in all three of these skin reactions. We report a 2-year-old girl who developed Stevens-Johnson syndrome-toxic epidermal necrolysis overlap after receiving ampicillin-sulbactam for an upper respiratory tract infection. She was treated successfully with a 4-day course of intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16060867     DOI: 10.1111/j.1525-1470.2005.22407.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  2 in total

1.  Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations.

Authors:  Christos S Zipitis; Nandu Thalange
Journal:  Eur J Pediatr       Date:  2006-09-29       Impact factor: 3.183

2.  Toxic epidermal necrolysis in an 8-year-old girl successfully treated with cyclosporin A, intravenous immunoglobulin and plasma exchange.

Authors:  Marzena Zielińska; Łukasz Matusiak; Waldemar Gołębiowski; Katarzyna Swiątek; Iwona Chlebicka; Joanna Maj; Jacek Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2018-04-24       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.